The CDC has issued its updated 2026 adult immunization schedule, adding refined RSV vaccine eligibility, annual COVID-19 boosters, and clarified pneumococcal options. The changes aim to simplify ...

Findings showed Capvaxive was noninferior to PPSV23 for each of the 12 serotypes present between the 2 vaccines. Topline data were announced from a phase 3 trial evaluating Merck’s 21-valent ...

Pneumococcal conjugate vaccines (PCVs) reduce disease and colonization by the serotypes they cover. As of now, the Advisory Committee on Immunization Practices (ACIP) recommends that PCV15 and PCV20 ...

The decision lowered the minimum recommended age by 15 years. U.S. health officials on Wednesday recommended that people 50 and older get a shot against bacteria that can cause pneumonia and other ...

—Among adults, coverage and preventable burdens were lowest for pneumococcal conjugate vaccine (PCV) 15 and highest for PCV31, with PCV21 preventing notable burdens of both acute respiratory ...

Pneumococcal disease is an infection caused by a bacteria called Streptococcus pneumoniae. There are about 100 different types (referred to as serotypes) of pneumococcal bacteria, which can affect ...

See more on Vaxcyte's (PCVX) and VAX-31’s broad pneumococcal vaccine pipeline, strong cash runway, and key 2026–2027 trial ...